{
  "report_rows": [
    {
      "kpi": "Brokerage Organic Growth (2Q 2026)",
      "prediction": "BEAT",
      "answer": "pred ~5.2% vs. cons 4.93%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Risk Mgmt Organic Growth (2Q 2026)",
      "prediction": "BEAT",
      "answer": "pred ~11.0% vs. cons 10.70%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Diluted Operating EPS (2Q 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.88 vs. cons $2.811",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Brokerage Organic FY 2026 (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~5.5% vs. cons 5.17%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Risk Mgmt Organic FY 2026 (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide ~8.0% vs. cons 8.06%",
      "confidence": "HIGH"
    },
    {
      "kpi": "Brokerage EBITDAC Margin FY 2026 (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 40-60 bps expansion vs. cons 35.76%",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 1.3,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 Archetype A historically follows through as sell-side revises FY estimates upward; muted by elevated pre-print setup (+30% idiosyncratic run since Q1 earnings)",
  "day5_confidence": "MEDIUM"
}